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Abstract
The clinical, biochemical and genetic features of the conditions known as estrogen-dependent inherited angioe-
dema, estrogen-associated angioedema, hereditary angioedema with normal C-1 inhibitor, type III angioedema, or
factor XII angioedema are reviewed. Discussion emphasizes pathogenesis, diagnosis, and management.
Review
Estrogen-dependent and estrogen-associated inherited
angioedemas were first described in 2000 [1,2], and
cases are increasingly recognized around the world
[3-7]. Recent studies offer new insights into the patho-
genesis and treatment of this condition, which have rele-
vance not only to these patients, but to those with
classic forms of hereditary angioedema as well. Encoura-
ging information on treatment of estrogen-related
angioedemas is becoming available.
Classic forms of hereditary angioedema
Classic forms of clinically recognized hereditary angioe-
dema (HAE), types I and II, are genetically heteroge-
neous autosomal-dominant disorders, characterized by
decreased levels, or function, respectively, of the inhibi-
tor for the first component of the complement pathway
(C1-INH) (Online Mendelian inheritance of man
[OMIM] 106100; http://www.ncbi.nlm.nih.gov/omim/)
Characteristic nonerythematous, non-pruritic swelling of
parts of the face, upper respiratory tract, gastrointestinal
tract, genitalia, hands and/or feet occur due to increased
production of bradykinin, formed as insufficient C1 INH
activity fails to restrict the action of factor XII and kal-
likrein [8-10].
Estrogen related angioedemas: nomenclature,
clinical and biochemical features
Novel forms of inherited angioedema, either completely
dependent on, or associated with high estrogen levels,
but otherwise clinically indistinguishable from classic
forms of HAE, were independently reported by North
American and European investigators in 2000 [1,2].
Cases are increasingly recognized around the world
[3-7]. The nomenclature of these conditions is evolving
as their underlying genetic abnormalities are elucidated.
Originally referred to by clinical phenotype as estrogen-
dependent (or estrogen-associated) inherited angioe-
dema (EDIA, EAIA) [1], HAE with normal C1-INH
activity [2]; or simply distinguished from classic forms
as HAE type III [OMIM 610618] [2], the terms Factor
XII-HAE or HAE-FXII have been used to identify the
condition when associated with the recently identified
gain-of-function mutation in the gene encoding factor
XII (F1 2 ) [11,12]. Some clinically indistinguishable
cases do not carry this mutation [11], so underlying
genetic diversity is apparent, and the nomenclature to
describe these conditions will likely continue to evolve.
Clinical heterogeneity is evident in described cases. In
a large multigenerational family of Italian origin, affected
individuals experienced angioedema only during preg-
nancy, use of oral contraceptives or hormone replace-
ment therapy [1]. In contrast, in different European
families, phenotypes were far more variable [2]. Some
patients experienced angioedema prior to menarche,
with exacerbations after puberty and/or with high estro-
gen states, but in many cases, angioedema occurred
even in low or normal estrogen level states. Initial
reports [1,2] described only affected female patients,
with an unaffected obligate male carrier [1]. More
recently, pedigrees with affected male members have
been described [13-15].
In one of the original reports [1], ethical considera-
tions precluded the study of biochemical features during
symptomatic episodes, as the index patients presented
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ters became pregnant during the period of observation.
As multiple family members had experienced laryngeal
edema during high estrogen states, investigators rea-
soned that administration of estrogen could have life-
threatening consequences, and affected individuals and
individuals of unknown phenotype were advised to
avoid estrogen. Indeed, death due to sudden airway
obstruction was reported in some family members in
the other originally reported pedigrees [2]. Thus, the
only available biochemical analyses, performed when the
affected individuals were asymptomatic, including nor-
mal C1-INH quantitative and functional assays, C3, C4,,
and factor XII levels, at the time did not allow the
investigators to preclude abnormalities in these para-
meters during symptomatic periods [1]. In the other
initial report [2], biochemical analyses were reported in
some symptomatic patients. C1 inhibitor level and activ-
ity, C3 and C4 were normal, even during acute attacks.
These observations helped to distinguish EDIA and
EAIA as being pathogenetically distinct from classic
forms of HAE.
Genetic features
The mode of inheritance could not be determined pre-
cisely in either of the original reports. Autosomal domi-
nant transmission was considered most likely in the
pedigree with strict estrogen dependence, though other
modes of transmission could not be excluded [1,2].
Detailed information was reported in two multigenera-
tional European pedigrees [2], one of which showed
transmission of disease to children from an unaffected
female, a phenomenon not seen in other reported pedi-
grees. Investigators speculated that the restriction to
women suggested an X-linked dominant mode of inheri-
tance; autosomal dominant transmission with hormonal
control of the expression of the trait (the favoured
explanation for the pedigree in the strictly estrogen-
dependent pedigree) was thought to be less likely due to
onset of symptoms in childhood, prior to significant
hormonal effects. Autosomal dominant transmission
seemed likely in a French pedigree [3] The recent iden-
tification heterozygosity for a gain-of-function mutation
in F12 in female subjects in patients with EAIA
[5,11,12,15,16] and EDIA, including those from the ori-
g i n a l l yr e p o r t e dp e d i g r e eo fI talian origin [17] suggests
that autosomal dominant transmission is likely. How-
ever, the involvement of other genetic polymorphisms
likely contributes to the diversity of clinical phenotypes
[17].
In the family of Italian origin, the coding sequences
as well as the 5’ untranslated region (UTR) of the
gene encoding C1 INH (SERPING1) were determined
to be normal, clearly establishing this condition as
being separate from the classic forms of hereditary
angioedema (characterized by mutational inactivation
of the C1 inhibitor gene). The 5’ UTR of F12 (known
to contain an estrogen-response element, alteration
of which might explain the clinical phenotype of
estrogen dependence) was also determined to be nor-
mal [1].
The biochemical and genetic observations from these
two studies indicated that abnormalities in C1 INH
could be excluded, and efforts to find the underlying
cause of EDIA/EAIA were redirected elsewhere.
On the basis of co-segregation patterns, two different
missense mutations in 6 index patients of 20 families
(confirmed in 22 additional family members), mapping
to 5 q 33-qter of F12 (Online Mendelian Inheritance in
Man, [OMIM] 610619) were identified in European ped-
igrees of hereditary angioedema with normal C1-INH.
Both in exon 9, one involved a threonine-to-lysine sub-
stitution (Thr309 Lys); the other a threonine-to arginine
substitution (Thr309Arg) [11]. The presence of
Thr328Lys in the family of Italian origin with estrogen-
dependent angioedema was confirmed in affected family
members living in Canada [17] and in Italy (R.
Colombo, personal communication),
In addition, affected family members living in Canada
were found to have polymorphisms in the genes for
angiotensin-converting enzyme (ACE) and aminopepti-
dase P (APP) that are associated with lower circulating
levels of these enzymes that are responsible for the
degradation of bradykinin and its active metabolite [17].
Insertion/deletion polymorphisms in the ACE gene
(ACE) account for 50% of the variability in human
serum levels of ACE [18], with the insertion (I) allele
associated with lower expression of ACE mRNA, and
decreased degradation of bradykinin [19]. All three
index patients had at least one copy of the inserted
allele (I) in intron 16 of the ACE gene that is associated
with lower levels of ACE.
Genetic variants in the gene encoding APP
(XPNPEP2), resulting in reduced enzyme activity, higher
bradykinin and des-Arg9-BK have been associated with
angioedema induced by ACE inhibitors [20]. All three
affected female subjects also had at least one copy of
the A allele at the SNP rs3788853 locus, located 5’ of
XPNPEP2, which codes for membrane-bound APP, and
is associated with decreased APP activity, decreased bra-
dykinin and des-Arg9-BK degradation, and angioedema
induced by ACE inhibitors [20,21]
Additional families with HAE and normal C1 inhibitor
have been identified as carrying the Thr328Lys mutation
[5,12,15,16,22], while other factor XII mutations have
been described in different pedigrees [23].
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pathway
A new picture is emerging of the hereditary angioede-
mas as a group of genetically heterogeneous disorders of
bradykinin metabolism, leading to its periodic accumula-
tion. Bradykinin and its active metabolite, des-Arg9-BK,
are the key mediators of angioedema [9,10,24,25]. Not
only can mutations in different components (C1 INH,
factor XII, ACE, APP, and as yet other, unidentified, fac-
tors) of bradykinin-related pathways occur, multiple dif-
ferent mutations can occur in each factor, and it seems
likely that different combinations of these mutations
contribute to the observed clinical heterogeneity of the
conditions. In addition, the unique sensitivity of many
of these components in bradykinin-related pathways to
androgens and estrogens further modifies the clinical
presentations. An appreciation of the pathways that
result in the formation and degradation of bradykinin,
and its active metabolite, des-Arg9-BK, and their regula-
tion by sex hormones, contributes to the rational treat-
ment of both classical and estrogen-dependent/factor
XII- associated forms of hereditary angioedema.
Effects of sex hormones on bradykinin pathways,
and contribution to clinical phenotype
Before considering the influence of the sex hormones on
key enzymes if bradykinin pathways, outlined below, it is
helpful to review key aspects of the reciprocal regulation
of bioavailable estrogen and testosterone through their
effects sex hormones binding globulin (SHBG) (reviewed
in [26]).
The activity of estrogen and testosterone is deter-
mined by the free or bioavailable fraction. In males,
approximately 65% of testosterone circulates bound to
SHBG, 78% in females. This bound fraction is essentially
a reservoir; only the remaining free testosterone is biolo-
gically active. The fraction of estrogen bound to SHBG
is less; only 30% is bound in males, 58% in females. The
clinical relevance of this differential binding is apparent
as abnormal variants of SHBG that bind sex hormones
less efficiently result in a preferential increase in bioa-
vailable testosterone with resulting masculinization.
By influencing the level of SHBG, each of the sex hor-
mones enhances its own bioavailability, while decreasing
the relative bioavailability of the other. For example,
estrogen increases levels SHBG, this in turn binds more
testosterone than estrogen, increasing the relative bioa-
vailability of estrogen. Conversely, androgens decrease
levels of SHBG, resulting in a preferential increase in
the bioavailability of androgens. This type of negative
reciprocal regulation of bioavailability can amplify the
effects of small changes in the relative amounts of estro-
gen versus testosterone, and may in part explain the
exquisite sensitivity of the clinical phenotype to rela-
tively small changes in sex hormones levels. Danazol has
been shown to suppress SHBG levels in classic HAE
patients [27], although other observations suggest there
may be additional effects of SHBG [28].
Estrogen: effect on bradykinin production
Factor XII
High levels of estrogen, such as occurr during pregnancy
or oral contraceptive use [29,30], are associated with
increased levels of factor XII, likely due to an estrogen-
response element in the promoter region of the gene
[31,32]. When activated, factor XII converts pre-kallik-
rein to kallikrein, which produces bradykinin from high
molecular weight kininogen. Under the conditions of
high estrogen levels, the increased availability of factor
XII for activation would favor increased bradykinin
production.
C-1 INH
High levels in estrogen during pregnancy [33-35], or
oral contraceptive use [36],are associated with reduced
levels of C-1 INH. As C-1 INH normally inhibits acti-
vated factor XII and kallikrein; reduced inhibition of fac-
tor XII and kallikrein with high estrogen levels would
favour increased bradykinin production.
Estrogen: effect on bradykinin degradation
ACE
Estrogen suppresses ACE expression [37]. As ACE is
important both for the degradation of bradykinin and its
active metabolite, des-Arg9-BK, reduced levels of ACE
under conditions of high estrogen levels result in
reduced degradation of bradykinin and its active meta-
bolite, favouring their accumulation.
APP
The effect of estrogen on APP levels is not known.
However, it has been reported that androgens increase
APP levels [38], and, as estrogen increases SHBG, and
reduces bioavailability of testosterone, it is reasonable to
speculate that estrogen might reduce APP levels. As
APP is particularly important in the degradation ofdes-
Arg9-BK, and to a lesser extent bradykinin itself,
reduced APP levels would favor the accumulation of
bradykinin.
Androgens: effect on bradykinin production
C-1 INH
Androgens increase the level of C-1 INH [39,40], which
in turn inhibits activated factor XII and kallikrein, redu-
cing bradykinin formation.
Factor XII
In rats, danazol was found to increase factor XII [41].
Specific studies in humans could not be located. Given
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HAE, one might speculate that the clinically beneficial
effects on other components of the bradykinin pathway
(increased C-1 INH, increased APP, with secondary
effects of the relative bioavailability of estrogen) out-
weigh the effect of increased factor XII. However, this
observation has intriguing consequences for HAE-FXII.
In this situation, androgen-induced increase in the over-
activeThr328Lys factor XII could be deleterious. This
has not been observed clinically [16], suggesting that, as
in classic HAE, beneficial effects of androgens on other
components of bradykinin metabolism overweight their
effects on factor XII.
Androgens: effect on bradykinin degradation
APP
Androgens increase APP levels [38]which would favor
bradykinin degradation.
ACE
Animal studies suggest androgens are responsible for
increased ACE levels [42,43]. Studies specifically addres-
sing the influence of androgens on human ACE levels
could not be located.
In summary, androgens and estrogens have reciprocal,
antagonistic effects on bradykinin metabolism through
their effects on multiple components in these pathways
relevant to the pathogenesis and treatment of classic
and estrogen-related HAEs. Primary effects result in
direct modification of the levels of key components in
the pathways for bradykinin formation and degradation.
Secondary effects, mediated through alterations in the
level of SBHG, may amplify these primary effects by
changing the relative bioavailability of the opposing sex
hormone. High estrogen levels result in conditions
favorable to increased bradykinin accumulation, whereas
high androgen levels result in conditions that lead to
low levels of bradykinin. The reciprocal antagonistic
effects on multiple key components of bradykinin meta-
bolism likely account for the sensitivity of disease
expression to small changes in hormone levels. Exquisite
sensitivity is most evident in patients with a strict estro-
gen-dependent phenotype [1]. For example, affected
members in the family with the F1 2Thr328Lys muta-
tion, the I allele of ACE, and the A allele of rs3788853
at the XPNPEP2 locus of the APP gene never experi-
enced angioedema during normal menstrual cycles;
however, angioedema occurred during pregnancy within
days of the first missed menstrual period, a time when
estrogen levels would be only marginally higher than the
end of a normal cycle.
Diagnosis
The diagnosis of estrogen-related HAEs remains chal-
lenging as there is no specific, readily available assay.
They should be suspected in the setting of otherwise
unexplained episodes of angioedema, occurring in, or
made worse, by high estrogen states, noting that strict
estrogen dependence does not occur in every pedigree,
even those with established factor XII Thr328Lys muta-
tions [16]. Classic forms of HAE can also be exacerbated
by high estrogen states, but these can be excluded if C-
4, C-1 INH function and C-1 INH activity are normal
[44]. Genetic analysis of suspected cases has been per-
formed a research basis, however, the methodology
required is likely within the capabilities of tertiary
genetic referral centres. Identification of pre-sympto-
matic individuals in established pedigrees should be a
priority so that exogenous estrogens (primarily oral con-
traceptives in young women) and the possibility of lar-
yngeal edema can be avoided.
Treatment: avoidance of aggravating medications
Two distinct classes of medications contribute to brady-
k i n i na c c u m u l a t i o na n ds h o u ld be avoided. Exogenous
estrogens (oral contraceptives and hormone replacement
therapy) have multiple effects that favour bradykinin
accumulation, and have been associated with clinical
exacerbations in both the estrogen-related [16] and clas-
sic forms of HAE [44]. Cardiovascular medications, ACE
inhibitors, act at single point in bradykinin degradation.
They have been associated with exacerbation of angioe-
dema in both classic and estrogen-related HAEs. One
patient experienced worsening of HAE-FXII with the
angiotensin II receptor blocker losartan [16]; the
mechanism for this effect is unclear. It would seem pru-
dent to avoid angiotensin receptor blockers in patients
with estrogen-associated HAE, if possible.
Treatment: acute management
Treatment experience of this newly recognized condi-
tion is limited; there are no well controlled trials. C1-
INH concentrate was moderately or very effective in 6/7
patients experiencing 63 angioedema attacks [16]. Pre-
sumably, the additional C-1 INH achieved this clinical
outcome by inhibiting activated factor XII and kallikrein,
preventing the positive feedback loops that amplify their
activity. The risks associated with this treatment would
be those associated with the use of blood products. It is
unclear if any of these reported uses occurred during
pregnancy. Recombinant C-1 INH would be expected to
have similar effects, but the potential for blood-borne
infections would be eliminated.
Fresh frozen plasma (FFP), is effective in classic forms
of HAE [45]; its use is considered if C-1 INH concen-
trates are not readily available to treat an acute attack.
Consideration of mechanisms responsible for bradykinin
accumulation in estrogen-related angioedemas suggests
FFP might be useful in these conditions. With respect to
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activity) might be expected to dilute theThr328Lys fac-
tor XII with increased activity, helping to return overall
factor XII activity towards normal, thereby reducing
further bradykinin formation. With respect to C1-INH,
transfusion of FFP would help replace any C-1 INH
consumed by uncontrolled factor XII and kallikrein acti-
vation, helping to restore appropriate levels of inhibition
of factor XII and kallikrein. With respect to the enzymes
responsible bradykinin degradation, ACE and APP,
transfusion of FFP would supplement levels in indivi-
duals having low levels of these enzymes due to genetic
polymorphisms of their corresponding genes, as in indi-
viduals described [17]. Therefore, there is a theoretical
basis for the use of FFP in estrogen-related angioedemas
if C-1 INH concentrates are not readily available to
treat an acute attack.
Ecallantide, is a potent, selective, reversible inhibitor
of kallikrein [46] that has recently become available for
clinical use. This compound blocks the binding site of
kallikrein, and reduces the conversion of high molecu-
lar weight kininogen (HMWK) to bradykinin. It also
prevents the positive feedback loop in which kallikrein
increases activation of factor XII, enhancing further
kallikrein production. This compound has been shown
to be effective in treating acute episodes of angioedema
in classic HAE [47]. There are no published reports of
its use in the estrogen-related angioedemas. No pub-
lished data regarding use in pregnancy could be
located.
Icatibant, a bradykinin receptor-2 antagonist has been
shown to be effective in ameliorating acute attacks of
classic HAE [48]. It may be useful in the estrogen-
related angioedemas [49].Safety during pregnancy is not
established.
Ineffective treatments include corticosteroids, in 27
patients, and antihistamines in 15 patients, which were
ineffective in controlling acute attacks [16], as is seen in
patients with classic HAE.
Treatment: prophylaxis
Progesterone use has been reported. Eight women on
various progesterone-only preparations were symptom
free during progesterone treatment [16], but the fre-
quency of previous attacks and whether these occurred
only during high estrogen states is not reported, so it is
difficult to evaluate whether the absence of symptoms
was attributable to the use of progesterone, or the
avoidance of estrogen. Further studies of the efficacy of
progesterone seem warranted in patients who experience
ongoing symptoms despite estrogen avoidance. How-
ever, caution is warranted as high progesterone levels
have been associated with a higher number of episodes
of angioedema in classic HAE [28].
Danazol use has been reported. Two patients experi-
enced amelioration of symptoms with danazol [16].
Though not stated specifically, it seems likely that
symptoms occurred during normal estrogen states.
Attenuated androgens act at many points in bradykinin
pathways to favour lower levels of bradykinin, thereby
ameliorating symptoms. Androgens have been a cor-
nerstone of treatment of classic HAEs for decades.
However, they are contraindicated in pregnancy due to
their masculinization of the fetus. The use of andro-
gens would likely be limited to patients who experi-
ence ongoing symptoms despite estrogen avoidance,
i.e., cases without strict estrogen dependence. For
example, in the family with the strict EDIA phenotype
[1] women of childbearing age were asymptomatic if
they avoided oral contraceptives and used alternate
methods of birth control, so androgens were not
required. Postmenopausal individuals were asympto-
matic if they avoided hormone replacement therapy
(one affected individual with severe menopausal symp-
toms was successfully managed with very low dose
transdermal estrogen without recurrence of angioe-
dema, K. Binkley, unpublished observation), so andro-
gens were not required. In this pedigree, identification
of the phenotype allowed symptoms to be successfully
managed by avoidance of triggers. Pregnancy was the
only state during which treatment would be required,
when androgens are contraindicated.
Tranexamic acid is used in classic forms of HAE, but
its efficacy is generally lower than that of the attenuated
androgens. It is thought that this antifibrinolytic agent
acts through the inhibition of plasmin. There is risk of
thromboembolic events with its use. Tranexamic acid
was used successfully in one patient with estrogen-
related angioedema [16]. It would seem the primary use
of this agent would be in cases in which angioedema
continued despite avoidance of estrogens.
In summary, various treatment options are available
for patients with estrogen-related angioedema that is
not controlled despite avoidance of exogenous estrogens,
though data is limited. The greatest need is for safe and
effective treatments for patients who desire pregnancy.
Currently, C-1 INH replacement with concentrates or
recombinant C-1 INH seemed to be the best options.
Conclusions
In the decade since their original description, signifi-
cant progress has been made in characterizing the
underlying responsible genetic abnormalities in the
estrogen-related HAEs. Significant clinical and genetic
heterogeneity in these conditions is apparent, and it is
likely that multiple genetic factors contribute to
disease expression, even within the same pedigree.
By extension, some of the more common genetic
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accumulation, reported in patients with EDIA, might
also contribute to the well-recognized phenotypic het-
erogeneity within individual pedigrees of classic HAEs.
The emerging picture is that both classic and estro-
gen-related HAEs belong to a family of diverse genetic
disorders of bradykinin metabolism that favour its per-
iodic accumulation, resulting in angioedema. In both
classic and estrogen-related HAEs, the profound effects
of estrogens and androgens on multiple components in
bradykinin metabolism pathways contribute to the
expression of clinical phenotype, and have important
implications for treatment. Limited data are encoura-
ging that C-1 INH replacement is effective in treating
acute attacks caused by mutations in F1 2 . Ecallantide
and icatibant may also be useful, but further studies
will be required. Optimal management of estrogen-
related angioedemas remains to be determined. Cur-
rently, definitive diagnosis remains challenging as
genetic analysis is not immediately available to most
clinicians. As these condition sa r ei n c r e a s i n g l yr e c o g -
nized, and the need for access to this analysis becomes
apparent, specialized tertiary and quaternary genetic
centres may be able to offer analysis in carefully
selected patients. The most pressing needs relate to
treatment during pregnancy, the one high-estrogen
state that patients may be unwilling to avoid, and the
one in which agents for long-term prophylaxis (andro-
gens and tranexamic acid) are contraindicated, and
safety data on agents used to treat acute attacks (C-1
INH replacement, kallikrein inhibitors, and bradykinin
receptor antagonists) is almost nonexistent. Large con-
trolled trials of treatment will be challenging due to
the heterogeneity and rarity of these conditions.
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